These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 36010904)
1. PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis. Mamat Yusof MN; Chew KT; Kampan N; Abd Aziz NH; Md Zin RR; Tan GC; Shafiee MN Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010904 [TBL] [Abstract][Full Text] [Related]
2. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis. Lu L; Li Y; Luo R; Xu J; Feng J; Wang M Front Oncol; 2020; 10():632. PubMed ID: 32426281 [No Abstract] [Full Text] [Related]
3. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis. Zhang C; Yang Q Front Oncol; 2020; 10():572203. PubMed ID: 33634012 [TBL] [Abstract][Full Text] [Related]
4. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis. Mamat Yusof MN; Chew KT; Hafizz AMHA; Abd Azman SH; Ab Razak WS; Hamizan MR; Kampan NC; Shafiee MN Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627060 [TBL] [Abstract][Full Text] [Related]
6. Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer: A Systematic Review and Meta-analysis. Blažek T; Petráš M; Knybel L; Cvek J; Soumarová R JAMA Netw Open; 2023 Mar; 6(3):e236324. PubMed ID: 37000447 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis. Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984 [TBL] [Abstract][Full Text] [Related]
8. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis. Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117 [TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. Pan ZK; Ye F; Wu X; An HX; Wu JX J Thorac Dis; 2015 Mar; 7(3):462-70. PubMed ID: 25922726 [TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
14. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis. Cai H; Zhang H; Jiang Y Front Oncol; 2020; 10():1079. PubMed ID: 32670887 [No Abstract] [Full Text] [Related]
15. Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis. Cui H; Li Y; Li S; Liu G Front Oncol; 2021; 11():693886. PubMed ID: 34490091 [TBL] [Abstract][Full Text] [Related]
16. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z Front Pharmacol; 2019; 10():962. PubMed ID: 31616289 [No Abstract] [Full Text] [Related]
17. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677 [No Abstract] [Full Text] [Related]
18. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L Front Pharmacol; 2019; 10():139. PubMed ID: 30873025 [No Abstract] [Full Text] [Related]
19. Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis. Fu H; Fu Z; Mao M; Si L; Bai J; Wang Q; Guo R Crit Rev Oncol Hematol; 2023 Sep; 189():104084. PubMed ID: 37536446 [TBL] [Abstract][Full Text] [Related]
20. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y Front Oncol; 2019; 9():897. PubMed ID: 31620360 [No Abstract] [Full Text] [Related] [Next] [New Search]